Paradigm Biopharmaceuticals Ltd
ASX:PAR
Gross Margin
Paradigm Biopharmaceuticals Ltd
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
Country | AU |
Market Cap | 94.9m AUD |
Gross Margin |
100%
|
Country | US |
Market Cap | 293.4B USD |
Gross Margin |
66%
|
Country | US |
Market Cap | 168.1B USD |
Gross Margin |
66%
|
Country | US |
Market Cap | 114.5B USD |
Gross Margin |
87%
|
Country | US |
Market Cap | 107.8B USD |
Gross Margin |
86%
|
Country | AU |
Market Cap | 135.3B AUD |
Gross Margin |
52%
|
Country | US |
Market Cap | 84.3B USD |
Gross Margin |
76%
|
Country | US |
Market Cap | 51.1B USD |
Gross Margin |
22%
|
Country | US |
Market Cap | 43.1B USD |
Gross Margin |
75%
|
Country | US |
Market Cap | 33.4B USD |
Gross Margin |
75%
|
Country | KR |
Market Cap | 39.7T KRW |
Gross Margin |
48%
|
Profitability Report
View the profitability report to see the full profitability analysis for Paradigm Biopharmaceuticals Ltd.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Paradigm Biopharmaceuticals Ltd's most recent financial statements, the company has Gross Margin of 99.9%.